About VLPbio
VLPbio is a company based in Boecillo (Spain) founded in 2011.. VLPbio has raised $998.38 thousand across 13 funding rounds from investors including HHS, Dyadic and European Union. VLPbio offers products and services including PCVax and TESTOP. VLPbio operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Boecillo, Spain
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vlp The Vaccines Company S.L
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$998.38 K (USD)
in 13 rounds
-
Latest Funding Round
$2.28 M (USD), Grant
May 01, 2019
-
Investors
HHS
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VLPbio
VLPbio offers a comprehensive portfolio of products and services, including PCVax and TESTOP. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Biotechnology-based vaccine against Porcine Circovirus for animal health
Immunocastrator vaccine for porcine animals to manage reproduction
Unlock access to complete
Unlock access to complete
Funding Insights of VLPbio
VLPbio has successfully raised a total of $998.38K across 13 strategic funding rounds. The most recent funding activity was a Grant round of $2.28 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Grant — $2.3M
-
First Round
First Round
(15 Mar 2011)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2019 | Amount | Grant - VLPbio | Valuation |
investors |
|
| Sep, 2018 | Amount | Grant - VLPbio | Valuation |
investors |
|
| Feb, 2018 | Amount | Seed - VLPbio | Valuation | Inveready , Dyadic |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in VLPbio
VLPbio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Dyadic and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Inveready is recognized as a leading Spanish financial services firm.
|
Founded Year | Domain | Location | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by VLPbio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - VLPbio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vlpbio Comparisons
Competitors of VLPbio
VLPbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about VLPbio
When was VLPbio founded?
VLPbio was founded in 2011.
Where is VLPbio located?
VLPbio is headquartered in Boecillo, Spain. It is registered at Boecillo, Castile And Leon, Spain.
Is VLPbio a funded company?
VLPbio is a funded company, having raised a total of $998.38K across 13 funding rounds to date. The company's 1st funding round was a Seed of $998.38K, raised on Mar 15, 2011.
What does VLPbio do?
VLPbio is a developer of virus-like particles as immunotherapies for cancer and infectious diseases. The technology is based on patented and proprietary antigen-display nano-platform based on Virus-Like Particles. This technology allows researchers to incorporate pathology-associated antigens into VLPs generating chimeric nanoparticles (Ch-VLPs). The pipelined products are PRRSVax for Porcine Reproductive Respiratory Syndrome, and Circovirus. For Humans, they are working on CerviVax, an immunotherapeutic vaccine for the treatment of HPV-16HPV-18 (Human Papilloma Virus) infections.
Who are the top competitors of VLPbio?
VLPbio's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
What products or services does VLPbio offer?
VLPbio offers PCVax and TESTOP.
Who are VLPbio's investors?
VLPbio has 5 investors. Key investors include HHS, Dyadic, European Union, Inveready, and EIC Fund.